Often, therapeutic development has focused on minute compounds, but peptidic partners are progressively demonstrating traction. This novel strategy utilizes combining peptides with alternative therapeutic methods to confront intricate disease pathways. By employing the specific features of amino acid sequences – such as high selectivity and bioav